total (n = 1158) | male (n = 666) | female (n = 492) | p value | |
---|---|---|---|---|
Antibodies positive rate during treatment | 7.3% (85/1158) | 4.4% (29/666) | 11.4% (56/492) | 0 |
TGAb | 4.2% (49/1158) | 1.7% (11/666) | 7.7% (38/492) | 0 |
TPOAb | 4.4% (51/1158) | 2.7% (18/666) | 6.7% (33/492) | 0.001 |
TRAb | 2.3% (27/1158) | 1.1% (7/666) | 4.1% (20/492) | 0.001 |
Median time to antibody positive (weeks) | 24 | 36 | 24 | 0.037 |
Negative conversion rates of antibody in 24 weeks | ||||
TGAb | 52.1% (25/48) | 81.8% (9/11) | 43.2% (16/37) | 0.025 |
TPOAb | 30.6% (15/49) | 25% (4/16) | 33.3% (11/33) | 0.553 |
TRAb | 53.6% (15/28) | 62.5% (5/8) | 50% (10/20) | 0.857 |